ArticleMetabolites2026
Polygoni Multiflori Radix Improves Dyslipidemia by Regulating Hepatocyte Lipid Metabolism Mediated via the AMPK/SREBP-2/PCSK9/LDLR Signaling Pathway.
Article in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo clarify the molecular mechanism of Polygoni Multiflori Radix in improving dyslipidemia and provide a scientific basis for its clinical application.
methodsNetwork pharmacology, molecular docking and simulation were used to predict and verify active components and core targets of Polygoni Multiflori Radix. HFD-induced hyperlipidemic mice were grouped and administered for 28 days; serum indices, hepatic pathology and AMPK/SREBP-2/PCSK9/LDLR pathway expression were detected.
resultsTwenty-two active components, 101 potential targets and the AMPK pathway (core) were identified. TSG, its main component, bound stably to AMPK/SREBP-2/PCSK9/LDLR. Polygoni Multiflori Radix dose-dependently improved HFD-induced abnormalities in mice (
conclusionsPolygoni Multiflori Radix effectively improves HFD-induced dyslipidemia by regulating the AMPK/SREBP-2/PCSK9/LDLR pathway to ameliorate hepatocyte lipid metabolism and reduce oxidative stress/liver injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.